Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Voclosporin

FDA-approved product (capsule, oral), marketed as Lupkynis.

Registered studies
28
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Voclosporin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Immune system disease
  • Lupus nephritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcineurin inhibitors
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

28registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Voclosporin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Voclosporin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone

    NCT07760480 · start 2026-04-23

    Registered record
    Registry ID
    NCT07760480
    Conditions
    Lupus Nephritis; Systemic Lupus Erythematosus (SLE)
    Interventions
    Kidney Biopsy; Voclosporin (LUPKYNIS); Blood, feces and urine sample collection; LupusPRO questionnaire; Mycophenolate Mofetil (MMF) Treatment; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-23
    Completion
    2030-04
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis; Systemic Lupus Erythematosus (SLE)
    InterventionKidney Biopsy; Voclosporin (LUPKYNIS); Blood, feces and urine sample collection; LupusPRO questionnaire +2 more
    PhasePhase 4
    Registry statusRecruiting

  • PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

    NCT07611214 · start 2026-04-22

    Registered record
    Registry ID
    NCT07611214
    Conditions
    Lupus Nephritis
    Interventions
    LUPKYNIS; belimumab, obinutuzumab or anifrolumab; mycophenolic acid analog (MPAA); corticosteroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-22
    Completion
    2029-03-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionLUPKYNIS; belimumab, obinutuzumab or anifrolumab; mycophenolic acid analog (MPAA); corticosteroid
    PhasePhase 4
    Registry statusRecruiting

  • LUPKYNIS Drug-use Results Survey

    NCT07053891 · start 2025-09-17

    Registered record
    Registry ID
    NCT07053891
    Conditions
    Lupus Nephritis
    Interventions
    Voclosporin (LUPKYNIS)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-17
    Completion
    2032-06-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionVoclosporin (LUPKYNIS)
    PhaseNot recorded
    Registry statusRecruiting

  • Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

    NCT07225387 · start 2024-10-01

    Registered record
    Registry ID
    NCT07225387
    Conditions
    Lupus Nephritis
    Interventions
    Voclosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-10-01
    Completion
    2027-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionVoclosporin
    PhasePhase 4
    Registry statusRecruiting

  • Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

    NCT05962788 · start 2024-03-28

    Registered record
    Registry ID
    NCT05962788
    Conditions
    Adolescent Lupus Nephritis; Pediatric Lupus Nephritis
    Interventions
    voclosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2024-03-28
    Completion
    2025-07-04
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdolescent Lupus Nephritis; Pediatric Lupus Nephritis
    Interventionvoclosporin
    PhasePhase 3
    Registry statusTerminated

  • A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

    NCT06406205 · start 2023-12-25

    Registered record
    Registry ID
    NCT06406205
    Conditions
    Lupus Nephritis
    Interventions
    Voclosporin（QL1074）; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-25
    Completion
    2028-06
    Enrolment
    270

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionVoclosporin（QL1074）; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

    NCT05288855 · start 2023-10-10

    Registered record
    Registry ID
    NCT05288855
    Conditions
    Adolescent Lupus Nephritis; Pediatric Lupus Nephritis
    Interventions
    Voclosporin; Placebo Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2023-10-10
    Completion
    2025-07-03
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdolescent Lupus Nephritis; Pediatric Lupus Nephritis
    InterventionVoclosporin; Placebo Oral Capsule
    PhasePhase 3
    Registry statusTerminated

  • Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

    NCT05306873 · start 2022-11-30

    Registered record
    Registry ID
    NCT05306873
    Conditions
    Systemic Lupus Erythematosus
    Interventions
    Mycophenolate Mofetil; Placebo for Mycophenolate Mofetil; Voclosporin; Placebo for Voclosporin; Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-11-30
    Completion
    2024-07-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus
    InterventionMycophenolate Mofetil; Placebo for Mycophenolate Mofetil; Voclosporin; Placebo for Voclosporin +1 more
    PhasePhase 2
    Registry statusTerminated

  • A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

    NCT05337124 · start 2022-04-05

    Registered record
    Registry ID
    NCT05337124
    Conditions
    Lupus Nephritis
    Interventions
    LUPKYNIS
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-04-05
    Completion
    2025-01-31
    Enrolment
    229

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionLUPKYNIS
    PhaseNot recorded
    Registry statusCompleted

  • Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin

    NCT05306379 · start 2022-01-24

    Registered record
    Registry ID
    NCT05306379
    Conditions
    Drug-drug Interaction
    Interventions
    Simvastatin; Voclosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-24
    Completion
    2022-04-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-drug Interaction
    InterventionSimvastatin; Voclosporin
    PhasePhase 1
    Registry statusCompleted

  • Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients

    NCT04701528 · start 2020-11-15

    Registered record
    Registry ID
    NCT04701528
    Conditions
    Covid19; Kidney Transplant Infection
    Interventions
    Voclosporin; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-11-15
    Completion
    2022-10-25
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Kidney Transplant Infection
    InterventionVoclosporin; Tacrolimus
    PhasePhase 2
    Registry statusCompleted

  • Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

    NCT04147650 · start 2019-10-14

    Registered record
    Registry ID
    NCT04147650
    Conditions
    Dry Eye Syndrome; Keratoconjunctivitis Sicca
    Interventions
    0.05% Voclosporin Ophthalmic Solution (VOS); 0.10% VOS; 0.20% VOS; Vehicle Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-10-14
    Completion
    2020-10-08
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndrome; Keratoconjunctivitis Sicca
    Intervention0.05% Voclosporin Ophthalmic Solution (VOS); 0.10% VOS; 0.20% VOS; Vehicle Ophthalmic Solution
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin

    NCT03597464 · start 2019-09-29

    Registered record
    Registry ID
    NCT03597464
    Conditions
    Lupus Nephritis
    Interventions
    Voclosporin; Placebo Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-29
    Completion
    2021-10-07
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionVoclosporin; Placebo Oral Capsule
    PhasePhase 3
    Registry statusCompleted

  • Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

    NCT03597139 · start 2018-08-13

    Registered record
    Registry ID
    NCT03597139
    Conditions
    Dry Eye
    Interventions
    Voclosporin Ophthalmic Solution; Restasis®
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-13
    Completion
    2018-12-13
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionVoclosporin Ophthalmic Solution; Restasis®
    PhasePhase 2
    Registry statusCompleted

  • Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

    NCT03598036 · start 2018-06-21

    Registered record
    Registry ID
    NCT03598036
    Conditions
    Focal Segmental Glomerulosclerosis
    Interventions
    Voclosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-06-21
    Completion
    2020-05-19
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocal Segmental Glomerulosclerosis
    InterventionVoclosporin
    PhasePhase 2
    Registry statusTerminated